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Background: Islet transplantation provides a promising cure for Type 1 diabetes; however it is limited by a
shortage of pancreas donors. Bone marrow-derived multipotent mesenchymal stem cells (MSCs) offer renewable
cells for generating insulin-producing cells (IPCs).
Methods: We used a four-stage differentiation protocol, containing neuronal differentiation and IPC-conversion
stages, and combined with pellet suspension culture to induce IPC differentiation.
Results: Here, we report adding extracellular matrix proteins (ECM) such as fibronectin (FN) or laminin (LAM)
enhances pancreatic differentiation with increases in insulin and Glut2 gene expressions, proinsulin and insulin
protein levels, and insulin release in response to elevated glucose concentration. Adding FN or LAM induced
activation of Akt and ERK. Blocking Akt or ERK by adding LY294002 (PI3K specific inhibitor), PD98059 (MEK specific
inhibitor) or knocking down Akt or ERK failed to abrogate FN or LAM-induced enhancement of IPC differentiation.
Only blocking both of Akt and ERK or knocking down Akt and ERK inhibited the enhancement of IPC
differentiation by adding ECM.
Conclusions: These data prove IPC differentiation by MSCs can be modulated by adding ECM, and these
stimulatory effects were mediated through activation of Akt and ERK pathways.
Background
Type 1 diabetes, caused by the autoimmune destruction
of pancreatic b-cells, is deficient in insulin and requires
exogenous insulin for treatment. Islet transplantation
offers a potential cure for type 1 diabetes [1]. However,
this approach is limited by a shortage of donor tissue
suitable for transplantation. One alternative to islet
transplantation is to implant a renewable source of insu-
lin-producing cells (IPCs).
Stem cells have the potential to multiply and differ-
entiate into any type of cells, thus providing cells that
can generate IPCs for transplantation.
Human multipotent mesenchymal stem cells (MSCs)
isolated from the bone marrow, can differentiate into
multiple mesenchymal cell types, including cartilage,
bone, and adipose tissues. They also display a neuronal
phenotype after induction with growth factors, neuro-
trophic factors or chemical products like retinoic acid or
3-isobutyl-1-methylxanthine (IBMX) [2-5]. Although
methods promoting neural differentiation have been
adapted to derive IPCs from embryonic stem cells [6-9],
such methods are insufficient to derive IPCs from MSCs
[10]. For future application of MSCs, many efforts have
been made to provide new protocols for differentiating
MSCs into IPCs [10-12].
Interaction of extracellular matrix proteins (ECM)
plays important roles in controlling cell proliferation,
motility, cell death and differentiation of stem cells or
progenitor cells. Pancreatic ECM mainly consists of
fibronectin (FN) and laminin (LAM). Pancreatic FN is
noted beneath the endothelial cells and epithelial ducts
[13], while LAM is mainly present in basement mem-
branes that form the interface between the epithelia and
connective tissues [14]. Both FN and LAM affect b-cell
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secretion [15]. We have also demonstrated adding FN
stimulated IPC differentiation by MSCs [10]; however,
the molecular signaling pathways that ECM mediate to
enhance IPC differentiation remain to be clarified.
Most of the MSCs used in previous studies were derived
from primary cell cultures. Primary cells harvested from
patients may have disease- or age-related differences such
that results may be donor specific. We therefore chose to
use an immortalized MSC line to provide more consistent
results for parametric studies designed to optimize differ-
entiation procedures. We also chose a four-stage differen-
tiation protocol, containing neuronal differentiation and
IPC-conversion stages, combined with pellet suspension
culture for getting efficient IPC differentiation [10]. In our
current study, we compared the effects of adding ECM
such as FN and LAM on the expression of Insulin and
Glucose transporter 2 (Glut2) genes and proinsulin and
insulin protein levels. We further clarified the underlying
mechanism that ECM mediated to enhance IPC differen-
tiation and found this effect is mediated through activation
of Akt and ERK.
Methods
Cell Lines and Culture Conditions
The human MSCs were established following retroviral
transduction with the type 16 human papilloma virus
proteins E6E7 and nucleoporation with human telomer-
ase reverse transcriptase (hTERT) as previously
described [3,16]. The cells were grown in a complete
culture medium [CCM: DMEM-low glucose (LG)
(Gibco, Grand Island, NY) supplemented with 10% fetal
bovine serum (FBS), 100 U/mL penicillin, and 10 μg/mL
streptomycin] at 37°C under 5% CO2 atmosphere. The
medium was changed twice a week and subculture was
performed at 1:5 split every week.
IPC differentiation protocol
For IPC differentiation in pellet suspension culture,
undifferentiated cells (stage 0) were suspended with
CCM and aliquots of 2.5×10
5 cells were placed in 15 ml
conical centrifuge tubes (Nalge Nunc International,
Rochester, NY), centrifuged at 600 g for 5 min, and cul-
tured in CCM for overnight. Then the pellets were lifted
to float in the medium by patting the tube and the med-
ium was replaced with CCM without (control) or with
adding 5 μg/mL fibronectin (bovine plasma; F1141,
Sigma) or laminin (basement membrane of Engelbreth-
Holm-Swarm tumor; L2020, Sigma) for 2 days (stage I).
At stage II, the pellets were switched into a medium
prepared from 1:1 mixture of DMEM/F-12 medium
containing 25 mM glucose (Invitrogen, Carlsbad, CA),
Insulin-Transferin-Selenium-A (ITS-A, Sigma), and 0.45
mM isobutylmethylxanthine (IBMX; Sigma) without or
with 5 μg/mL fibronectin or laminin for 1 day. Then the
pellets were transferred into DMEM/F-12 medium con-
taining 5.56 mM glucose, 10 mM nicotinamide (Sigma),
N2 supplement (Invitrogen), and B27 supplement (Invi-
trogen) without or with 5 μg/mL fibronectin or laminin
for 4 days (stage III). At stage IV, pellets were trans-
ferred into a medium with the same supplements at
stage III but containing 25 mM glucose for 3 days. For
identifying signaling pathways involved in IPC differen-
tiation by MSCs, LY294002 (50 μM; Cell Signaling
Technology) or/and PD98059 (50 μM; Cell Signaling
Technology, Beverly, MA) were added from the start of
stage III to the end of stage III.
RT-PCR and quantitative RT-PCR
Total RNA was prepared by using the TRIzol® Reagent
(Invitrogen). For cDNA synthesis, random sequence pri-
mers were used to prime the reverse transcription reac-
t i o n sa n ds y n t h e s i sw a sc a r r i e do u tb yS u p e r S c r i p t ™ III
Reverse Transcriptase (Invitrogen). A total of 35 cycles of
PCR were performed using Taq DNA polymerase
Recombinant (Invitrogen). The reaction products were
resolved by electrophoresis on a 1.2% agarose gel and
visualized using ethidium bromide with the housekeeping
gene (b-actin) as a control. For real-time PCR, the ampli-
fication was carried out in a total volume of 25 μLc o n -
taining 0.5 μM of each primer, 4 mM MgCl2,1 2 . 5μL
of LightCycler™-FastStart DNA Master SYBR green I
(Roche Molecular Systems, Alameda, CA) and 10 μLo f
1:20 diluted cDNA. PCR reactions were prepared in
duplicate and heated to 95°C for 10 min followed by 40
cycles of denaturation at 95°C for 15 seconds, annealing
at 60°C for 1 min, and extension at 72°C for 20 seconds.
Standard curves (cycle threshold values versus template
concentration) were prepared for each target gene and
for the endogenous reference (GAPDH) in each sample.
The quantification of the unknown samples was
performed by the LightCycler Relative Quantification
Software version 3.3 (Roche).
Immunohistochemistry
Suspension cell pellets were fixed in 4% paraformalde-
hyde, then dehydrated and embedded in paraffin. Immu-
nohistochemistry was performed on 4-μm tissue sections.
The sections were first reacted with primary antibodies
against human insulin (anti-insulin, 1:200; Chemicon,
Temecula, CA) and proinsulin (anti-proinsulin, 1:200;
Chemicon) followed by incubation with biotinylated
secondary antibodies. Detection was accomplished using
streptavidin-peroxidase conjugate and diaminobenzidine
(DAB) as a substrate (LAB Vision, Fremont, CA). Coun-
terstaining was carried out with hematoxylin. Finally, the
slides were mounted and analyzed using an optical
microscope.
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Page 2 of 10In Vitro Insulin Release Assay
Cell pellets after differentiation were rinsed twice in PBS
and Krebs-Ringer bicarbonate (KRB) buffer (120 mM
NaCl, 5 mM KCl, 2.5 mM CaCl2, 1.1 mM MgCl2,2 5m M
NaHCO3, 0.1 g BSA) and preincubated for 1hour with
KRB buffer containing 5 mM glucose. The pellets were
then incubated for 1 hour in fresh KRB buffer with
5 mM, 10 mM, 15 mM or 25 mM glucose. Different ago-
nists and antagonists of signal pathway of insulin release
were added, including IBMX (100 μM) and nifedipine
(50 μM) (Sigma). Insulin levels were measured using an
enzyme-linked immunosorption assay (ELISA), which
detects human insulin but not proinsulin or c-peptide.
Cell Viability Assay
Cell viability was measured by 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) dye absor-
bance according to the manufacturer’s instructions
(Boehringer Mannheim, Mannheim, Germany). Cells
were seeded in 96-well plates at a density of 10,000 per
well. Cells were incubated without or with LY294002
(50 μM) or PD98059 (50 μM) for 48 hours. Cell viability
was determined using MTT assay. Each experimental
condition was done in triplicate and repeated at least
once.
Western Blotting
Cell lysates were prepared using protein extraction
reagent (M-PER, Pierce, Illinois) plus protease inhibitor
cocktail (Halt, Pierce). Protein concentrations were
determined using the BCA assay (Pierce). After being
heated for 5 min at 100°C in a sample buffer, aliquots of
the cell lysates were run on a 10-12% SDS-polyacryla-
mide gel. Proteins were transferred to PVDF membrane.
The membrane was blocked for more than 1 hour and
then incubated overnight at 4 °C with the primary anti-
bodies such as phosphate-ERK (Thr202/Tyr204) (Cell
Signaling Technology), total-ERK (Cell Signaling Tech-
nology), phosphate-Akt (Cell Signaling Technology),
total-Akt (Cell Signaling Technology) and Actin (Santa
Cruz Biotechnology, Santa Cruz, CA). The membrane
was washed and bound primary antibodies were
detected by incubating at room temperature more than
1 hour with horseradish peroxidase-conjugated goat
anti-rabbit IgG (Santa Cruz Biotechnology) and anti-
goat IgG (Santa Cruz Biotechnology) for Actin. The
membrane was washed and developed using a chemilu-
minescence assay (Perkin-Elmer Instruments, Inc. Bos-
ton, MA).
Lentiviral-Mediated RNAi
The expression plasmids and the bacteria clone for
Akt shRNA (TRCN0000010062) and ERK shRNA
(TRCN0000010049) were provided by the National
Science Council in Taiwan. Lentiviral production was
done by transfection of 293T cells using Lipofectamine
2000 (LF2000; Invitrogen, Carlsbad, CA). Supernatants
were collected 48 h after transfection and then were
filtered. Subconfluent cells were infected with lentivirus
i nt h ep r e s e n c eo f8μg/mL polybrene (Sigma-Aldrich).
At 24 hours post-infection, we removed medium
and replaced with fresh growth medium containing pur-
omycin (1 μg/mL) and selected for infected cells for
48 hours.
Results
FN and LAM enhance differentiation of MSCs into insulin
producing cells
To examine the effects of ECM, FN and LAM on IPC dif-
ferentiation by MSCs, a four-stage differentiation proto-
col in suspension pellet culture [10] was performed and
gene expression profiles for neural and pancreatic islet
differentiation markers were assessed using RT-PCR for
the stage IV cells. Nestin, the marker of neural precursor
was expressed by MSCs both with and without FN and
LAM. MSCs with or without these ECM also expressed
genes specifying transcription factors essential for in
vivo differentiation of IPCs, including Nkx6.1 and Ngn3
(Figure 1A). There was no obvious difference between
the expression of these genes in cells treated with or
without ECM. We then quantified the gene expression of
insulin and Glut2. RT-PCR revealed adding FN or LAM
increased the expression of Insulin and Glut2 (Figure
1A). Furthermore, quantitative RT-PCR showed adding
FN and LAM increased the gene expression of insulin
5-fold and 52-fold, respectively (Figure 1B); and increased
the gene expression of Glut2 4-fold and 29-fold, respec-
tively (Figure 1C), compared to the cells without added
ECM. However, combining FN and LAM did not further
increase the expression of insulin and Glut2 (Figure 1),
suggesting FN and LAM did not work synergistically to
enhance IPC differentiation.
Immunohistochemistry (IHC) in stage IV cells further
revealed adding ECM increased the percentage of proin-
sulin and insulin expressing cells with the maximum
effect seen in cells treated with LAM (Figure 2). These
data are consistent with the mRNA levels of Insulin and
Glut2 and all demonstrate LAM has greater ability than
FN to stimulate IPC differentiation. These results indi-
cate adding ECM, especially LAM, enhances differentia-
tion of MSCs into IPCs.
FN and LAM increases insulin release after glucose
challenge
To quantify functional insulin release by stage IV cells,
we used glucose-challenge test and assayed with a
human insulin ELISA. A baseline release of insulin by
stage IV cells was detected at 5 mM glucose, while the
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Page 3 of 10Figure 1 Adding FN or LAM during differentiation enhances expression of insulin and Glut2. MSCs were induced by four-stage protocol, and
(A) RT-PCR and quantitative RT-PCR for (B) insulin and (C) Glut2 were performed at stage IV. Adding FN or LAM does not increase the expression of
Nestin, Ngn3 and Nkx6.1, but increases the expression of Insulin and Glut2. (mean ± S.D.; **indicates significant difference (P < 0.01) compared with
control by student’s t test.)
Figure 2 Adding FN or LAM during differentiation enhances protein levels of proinsulin and insulin.M S C sw e r ei n d u c e db yf o u r - s t a g e
protocol, and immunohistochemistry was performed for stage IV cells. (A) Immunohistochemistry shows the expression of insulin and proinsulin in
stage IV cells. Quantification of IHC staining shows FN and LAM increases the percentage of (B) proinsulin, and (C) insulin positive cells. (mean ± S.D.;
** indicates significant difference (P < 0.01) compared with control by student’s t test.) (Bar = 100 μm).
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Page 4 of 10increase in glucose concentration to 10, 15 or 25 mM
significantly increased insulin release with the greatest
release at 15 mM (Figure 3A). These results suggest the
release of insulin is dependent on extracellular glucose
concentration. Both FN and LAM increased insulin
release by stage IV cells at glucose concentrations of 10,
15 and 25 mM. The greatest difference of insulin release
by cells treated with or without ECM was noted at
10 mM glucose, where FN and LAM increased insulin
release roughly 1.8-fold and 2-fold, respectively, com-
pared to cells without ECM. To determine if the cell
pellets used physiological signaling pathways to regulate
insulin release, we examined the effects of several ago-
nists or antagonists on insulin release of ECM-induced
cell pellets. Agonist- IBMX, an inhibitor of cyclic-AMP
(cAMP) phosphodiesterase, stimulated insulin release
i nt h ep r e s e n c eo fl o wg l u c o s ec o n c e n t r a t i o n( 5m M )
(Figure 3B). Conversely, antagonist- nifedipine, a blocker
of L-type Ca2 + channel (one of the Ca2 + channel pre-
sent in b-cells), inhibited insulin release in the presence
of 10 mM glucose concentration (Figure 3C). These
results demonstrate stage IV cells secrete insulin in
response to an increase in glucose concentration using
the normal secreting mechanism of pancreatic islets.
FN and LAM enhances activation of Akt and ERK
The ECM bind to cells by activating signaling molecules
such as Akt and ERK. Therefore, we analyzed the effect
of FN and LAM on the phosphorylation status of Akt
and ERK for stage III cells. There was a baseline of Akt
and ERK phosphorylation without adding ECM. FN and
LAM increased phosphorylation of Akt and ERK, and
LAM had greater effects on Akt and ERK activation
than FN (Figure 4A). FN and LAM activated phosphory-
lation of AKT approximately 1.7-fold and 2.1-fold com-
pared to the control, respectively (Figure 4B), and
activated phosphorylation of ERK roughly 2.4-fold and
4-fold compared to the control, respectively (Figure 4C).
These results showed both FN and LAM could enhance
the phosphorylation of Akt and ERK.
Figure 3 Adding FN or LAM during differentiation increases insulin release in response to elevated glucose concentration. MSCs were
induced by four-stage protocol, and ELISA analysis for insulin release was performed for stage IV cells. (A) Insulin release at different glucose
concentrations. Insulin release before and after treatment with (B) IBMX or (C) nifedipine. (mean ± S.D.; *P < 0.05 and **P < 0.01 compared with
control by student’s t test. ##P < 0.01 by student’s t test.)
Figure 4 Adding FN or LAM increases the activation of Akt and ERK. (A) MSCs were induced for differentiation without (Control) or with FN
or LAM, and western blotting was done for stage III cells. Quantification of western blotting shows FN or LAM increases the activation of (B) Akt
and (C) Akt. (mean ± S.D.).
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depends on Akt and ERK activation
To examine the involvement of Akt and ERK activa-
tion in enhancing IPC differentiation by FN and LAM,
the cells were pretreated with LY294002 (a specific
inhibitor of PI3 Kinase) or PD98059 (a specific inhibi-
tor of MEK 1) followed by induction with FN or LAM.
Treatment with 50 μM of LY294002 or PD98059 did
not induce any decrease in cell growth in MSCs (Fig-
ure 5A), suggesting these two reagents did not induce
significant cytotoxicity. LY294002 decreased the activa-
tion of Akt both in cells treated with FN or LAM (Fig-
ure 5B and 5C). Surprisingly, we also found LY294002
increased the activation of ERK approximately 1.7-fold
and 2.1-fold compared to FN and LAM treated con-
trols, respectively (Figure 5C). On the other hand,
PD98059 decreased the activation of ERK both in cells
treated with FN or LAM (Figure 5B and 5D) and
increased the activation of Akt about 2.7-fold and 2.1-
fold compared to FN and LAM treated controls,
respectively (Figure 5D). Treatment with both
LY294002 and PD98059 followed by treatment with
FN or LAM decreased activation of both Akt and ERK
( F i g u r e6 A ,Ba n d6 C ) .T h e s ed a t as u g g e s tc r o s s - t a l k
between MEK-ERK and PI3K-Akt pathways in FN and
LAM-induced enhancement of IPC differentiation. We
then analyzed the effects of treatment with LY294002
and PD98059 on the expression of insulin and Glut2.
Quantitative RT-PCR showed insulin and Glut2
expression increased by treatment with PD98059 or
LY294002 (Figure 5E and 5F). However, treated with
both LY294002 and PD98059 decreased the expression
of insulin and Glut2 (Figure6 D ) .U s i n gt h ev e c t o r -
based RNAi approach, we further showed knocking
down Akt or ERK failed to abrogate FN or LAM-
induced enhancement of IPC differentiation. Only
knocking down both of Akt and ERK inhibited the
enhancement of IPC differentiation by adding ECM
(Figure 7). These results all together point out FN and
LAM both increased IPC differentiation by Akt and
ERK activation.
Discussion
There is a widespread interest in finding alternative
sources of b-cells for tissue replacement strategies in
diabetes. MSCs have been used for cell-based therapy in
regenerative medicine and tissue engineering. In the
current study, we demonstrate adding ECM does not
influence the expression of the neural precursor marker
and islet transcription factors, but heightens IPC differ-
entiation. Because MSCs spontaneously express the
neural precursor maker, Nestin, and transcription fac-
tors of the endocrine pancreas developmental pathway
Figure 5 Cross-talk between PI3K-Akt and MEK-ERK pathways
during differentiation of MSCs into IPCs. (A) MSCs were treated
without (DMSO) or with 50 μM of PD98059 or LY294002 and MTT
assay were performed at 48 hours. (B) MSCs were pretreated
without (DMSO) or with PD98059 or LY294002 at stage III during
differentiation with FN or LAM, and western blotting was done for
stage IV cells. Quantification of Akt (C) and ERK (D) phosphorylation
shows PD98059 and LY294002 increase the activation of Akt and
ERK, respectively. Quantitative RT-PCR for (E) insulin and (F) Glut2
expression shows both PD98059 and LY294002 increase the
expression of insulin and Glut2. (mean ± S.D.; **indicates significant
difference (P < 0.01) compared with control by student’s t test.).
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Page 6 of 10Figure 6 FN or LAM enhances IPC differentiation by activating Akt and ERK. (A) MSCs were pretreated without (DMSO) or with both
PD98059 and LY294002 (PD+LY) at stage III during differentiation with FN or LAM, and western blotting was done for stage IV cells.
Quantification of Akt (B) and ERK (C) phosphorylation shows adding both PD98059 and LY294002 decreases the activation of Akt and ERK. (D)
Quantitative RT-PCR for insulin and Glut2 expression shows adding both PD98059 and LY294002 decreases the expression of insulin and Glut2.
(mean ± S.D.).
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Page 7 of 10Figure 7 The involvement of Akt and ERK activation in FN or LAM-induced enhancement of IPC differentiation.( A )M S C sw e r e
transduced with scrambled (-) or siRNA against ERK (siERK) and Akt (siAkt) and induced for IPC differentiation with FN or LAM, and western
blotting was done for stage IV cells. Quantification of Akt (B) and ERK (C) phosphorylation after transduction with siERK and siAkt. Quantitative
RT-PCR for (D) insulin and (E) Glut2 expression shows transduction with either siERK or siAkt increases the expression of insulin and Glut2, and
transduction with both siERK and siAkt decreases the expression of insulin and Glut2. (mean ± S.D.; *p < 0.05 and **p < 0.01 compared with the
scrambled as determined by the student’s t test.).
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Page 8 of 10such as Nkx6.1 and Ngn3 [8,10], expression of these
markers or factors is insufficient to trigger IPC differen-
tiation, which requires further pathways to complete.
ECM provide a dynamic microenvironment to regulate
cell morphology, motility, gene expression and survival
of adherent cells [17]. FN and LAM constitute the
major ECM of pancreas islet cells. Laminin-1 has been
reported to promote the differentiation of fetal mouse
pancreatic b-cells [18]. Both FN and LAM have been
shown to affect the proliferation and insulin release of
b-cell [15,19,20]. The current study demonstrates treat-
ment of MSCs with FN or LAM enhances IPC differen-
tiation with increases in insulin and Glut2 gene
expressions, proinsulin and insulin protein levels, accu-
mulation of cytoplasmic granules including a, b,a n dδ
granules, and insulin release in response to elevated glu-
cose concentration. Failure to form typical b-cell gran-
ules was noted in the IPCs derived from embryonic
stem cells [21]. Thus, the appearance of three-kinds of
pancreas cytoplasmic granules in these results further
indicates the complete achievement of IPC differentia-
tion by adding FN or LAM during differentiation.
Although the benefits of ECM on insulin expression
and release are known in b-islet cells [15,19,20], the
underlying mechanisms are not clear. This paper
demonstrates ECM such as FN or LAM enhances IPC
differentiation by activating Akt and ERK. The ERK
pathway is the cascade most often associated with sig-
naling mechanisms involved in cell proliferation and cell
cycle progression but more recently also in apoptosis
[22]. Akt protein, a serine/threonine kinase promotes
cell cycle progression, cell survival, and tumour cell
invasion [23]. The b-cell proliferation and differentiation
are regulated by various growth factors and hormones,
including insulin-like growth factor 1 (IGF-1). Treat-
ment of islets with IGF-1 induces GRF-1-dependent
activation of downstream signals such as Akt and ERK
to maintain a normal b-cell number and function [24].
However, there are few, if any, papers reporting the
involvement of ERK or Akt in ECM or biomaterials-
induced enhancement of IPC differentiation.
Although, when bone marrow-derived endothelial cells
[25] or stem cells [26] were transplanted, they migrated
to the site of pancreatic b-cell injury and initiated pan-
creatic regeneration. These data suggest the paracrine
effects of bone marrow cells on supporting endogenous
cells to regenerate. However, the potential of bone mar-
row stem cells or MSCs to differentiate into IPCs has
been demonstrated in vitro and in vivo. Bone marrow
cells when transplanted into lethally irradiated recipient
mice expressed insulin in the pancreatic islets of the
recipient mice [27]. This study and others [8] have
demonstrated human MSCs spontaneously expressed
transcription factors of the endocrine pancreas
developmental pathway. It has also been shown mouse
marrow MSCs cultured in high glucose for 4 months or
rat marrow MSCs cultured with pancreatic extract
induces several b-cell-specific genes [28]. Here, adding
F No rL A Mi np e l l e ts u s p e n s i o nc u l t u r ee f f i c i e n t l y
induce IPC differentiation by MSCs and succeeded in
developing glucose responsive IPCs in vitro. Therefore,
the current study offers a potential approach to generate
IPCs from MSCs by adding ECM or biomaterials in pel-
let suspension culture, and demonstrates IPC differen-
tiation by MSCs may be modified in the future by
controlling Akt and ERK signaling pathways involved in
ECM interaction.
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